Efficacy and long-term safety of ospemifene in the treatment of vulvar and vaginal atrophy (VVA) in postmenopausal women: A 52-week, randomized, double-blind, placebo-controlled, parallel-group study comparing 60 mg oral daily dose of ospemifene with placebo.

Trial Profile

Efficacy and long-term safety of ospemifene in the treatment of vulvar and vaginal atrophy (VVA) in postmenopausal women: A 52-week, randomized, double-blind, placebo-controlled, parallel-group study comparing 60 mg oral daily dose of ospemifene with placebo.

Completed
Phase of Trial: Phase III

Latest Information Update: 14 Jul 2016

At a glance

  • Drugs Ospemifene (Primary)
  • Indications Atrophic vaginitis; Vulval disorders
  • Focus Adverse reactions; Registrational; Therapeutic Use
  • Sponsors Hormos Medical; Shionogi
  • Most Recent Events

    • 06 Oct 2012 Tolerability results presented at the 23rd Annual Meeting of the North American Menopause Society.
    • 18 Apr 2012 New source identified and integrated (ClinicalTrials.gov: US National Institutes of Health; NCT00566982).
    • 18 Apr 2012 Company (Shionogi) added as trial sponsor as reported by ClinicalTrials.gov.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top